A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Cediranib (Primary)
- Indications Alveolar soft part sarcoma
- Focus Therapeutic Use
- Acronyms CASPS
- 02 Jun 2017 Primary endpoint (Percentage change in the sum of target marker lesion diameters (TMLsum) from randomisation to week 24 (or progression if sooner) compared to treatment with placebo) has been met, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Aug 2016 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.